RxDoctor Payments Data

Karen Reynolds, MD

Family Medicine · Macon, GANPI 1598832792

Payments from drug & device makers

$643in general payments, 2019–2025

Across 26 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$150
  • Novo Nordisk$135
  • Abiomed$54
  • Sanofi-aventis U.S. LLC$52
  • Bayer$48
  • Exact Sciences$39
  • plus $165 from 7 others

What the payments were for

  • Food & beverage$643100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$150
Novo Nordisk6$135
Abiomed2$54
Sanofi-aventis U.S. LLC3$52
Bayer2$48
Exact Sciences2$39
Lilly USA, LLC2$34
Boehringer Ingelheim2$33
Bardy Diagnostics, Inc.1$24
AbbVie1$22
Amgen1$18
Ardelyx, Inc.1$17
GSK1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$643 in reported general payments places this provider in the 50th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$1,894
Medicare patients
16
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$28,711
EliquisApixaban25$28,390
MounjaroTirzepatide15$26,919
TrulicityDulaglutide12$21,663
Tresiba Flextouch U-100Insulin Degludec14$11,271
Albuterol Sulfate HfaAlbuterol Sulfate21$1,309
Gabapentin49$862
Atorvastatin Calcium120$853
Losartan Potassium57$611
Amlodipine Besylate116$519
Duloxetine Hcl17$360
Omeprazole26$309
Pantoprazole Sodium28$284
Tamsulosin Hcl13$237
Metoprolol Succinate26$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$34$48,58227 claims
Novo NordiskOzempic$135$28,71114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →